Several institutions report advances in cancer genomic profiling and diagnostics. Caris Life Sciences completed a $494 million IPO highlighting their AI-driven multimodal clinico-genomic platform used to identify disease patterns and treatment options. Invivoscribe secured New York State approval for its NPM1 minimal residual disease assay in AML patients, complementing existing assays guiding therapy selection. Intelliseq partnered with Genomenon to integrate somatic variant data enhancing cancer genomic interpretation and personalized treatment capabilities.